skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Bivalent HPV16/18 Therapeutic Cervical Cancer Vaccine (Code C112207)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Bivalent HPV16/18 Therapeutic Cervical Cancer Vaccine

Definition: A bivalent human papillomavirus (HPV) therapeutic vaccine containing recombinant inactivated adenylate cyclase (CyaA) from Bordetella pertussis carrying a sequence encoding the E7 antigen of both HPV16 and 18, with potential immunostimulatory and antiviral properties. Upon administration of bivalent HPV16/18 therapeutic cervical cancer vaccine, the expressed proteins may activate cell-mediated immunity and induce both cytotoxic CD8+ T cells and CD4+ helper T cells against the target antigens HPV16-E7 and HPV18-E7, which leads to HPV viral clearance. Adenylate cyclase is a virulence factor of Bordetella pertussis. Its ability to bind to CD11b-expressing dendritic cells and deliver antigens directly to the cytosol allows the activation and induction of T-cell immunity. CyaA may also induce a B cell response.

Label: Bivalent HPV16/18 Therapeutic Cervical Cancer Vaccine

NCI Thesaurus Code: C112207 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL454407  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Bivalent HPV16/18 Therapeutic Cervical Cancer Vaccine

External Source Codes: 
PDQ Closed Trial Search ID 754307
PDQ Open Trial Search ID 754307 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C112207
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom